Frontline Therapy in Chronic Lymphocytic Leukemia

Abstract

<b><i>Background:</i></b> The treatment landscape of chronic lymphocytic leukemia (CLL) has tremendously evolved in the last decades, thanks to the introduction of more effective therapies. <b><i>Summary:</i></b> Frontline therapy for patients with CLL includes chemoimmunotherapy (CIT) and pathway inhibitors (PIs) (i.e., bruton tyrosine kinase inhibitors and BCL2 inhibitors); the latter has proved to be more effective than CIT mainly in patients with high-risk features (e.g., <i>TP53</i> aberrations and unmutated IGHV) with acceptable toxicity. Combinations of PIs are playing the protagonist role as frontline therapy for CLL. <b><i>Key Messages:</i></b> In this article, the management of treatment-naïve patients with CLL is discussed.